All Invest Securities reiterates buy on ABL Texcell Diagnostics, keeps target at EUR 8.7

• All Invest Securities reiterated a Buy rating on ABL Texcell Diagnostics in an Oct. 8, 2026 research flash note.
• Target price held at EUR 8.7 per share, citing expectations for continued revenue growth beyond 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008383310) on October 08, 2026, and is solely responsible for the information contained therein.